Healthcare Industry News: IDev Technologies
News Release - October 21, 2010
IDEV Technologies Launches Additional Products in EuropeNew Sizes of SUPERA® Stent Expand Treatment Options for Peripheral Vascular Disease
WEBSTER, Texas, Oct. 21 -- (Healthcare Sales & Marketing Network) -- IDev Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients with peripheral vascular disease with the addition of two longer stents to its SUPERA product line. The initial uses of the newly introduced 180mm and 200mm stents occurred in August of this year, followed by a full European market launch at the recent European Society of Vascular Surgery meeting held this past September, in Amsterdam.
"We are very pleased with the acceptance of these new longer stents. Our goal is to provide the broadest and most effective line of products for treating patients with peripheral vascular disease. The successful launch of these additional SUPERA sizes moves us closer to reaching that goal and achieves our objective of launching multiple new products in Europe this year," stated Christopher M. Owens, President and CEO of IDEV.
The launch of these devices follows the recent introduction of the SUPERA VERITAS™ Peripheral Vascular System, an easy to use, reliable and more precise delivery system developed to deliver the SUPERA stent.
Peter Haarbrink, MD, a leading interventional radiologist affiliated with Canisius Wilhelmina Ziekenhuis (CWZ), a large general and teaching hospital located in Nijmegen, The Netherlands, said, "The availability of these new sizes has given me even more options for treating patients with peripheral vascular disease. The unique and exceptional stent properties, combined with the ease of delivery with the new VERITAS™ system, create a true advancement in technology."
Dierk Scheinert, MD, and Chairman of the Center for Vascular Medicine at the Park Hospital, Leipzig, Germany, was one of the first to deploy the longer sizes. He concluded, "I've used the SUPERA product for several years and appreciate the ongoing enhancements to the system. First VERITAS made it easier and more accurate to deploy the stent. Now the 180mm and 200mm sizes allow me to treat longer and more difficult lesions, they deploy easily and add to a broad stent portfolio."
About IDev Technologies, Incorporated
IDev Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology marketplace. IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands. Please visit www.idevmd.com.
The SUPERA stent is currently indicated in the US for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe for both the treatments of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).
Source: IDEV Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.